Conditions currently associated with erythema nodosum in Swiss children

A review was made of the 36 paediatric patients in whom the diagnosis of erythema nodosum had been established between 1977 and 1996 at the Department of Paediatrics, University of Bern, Switzerland. Infectious diseases were associated with erythema nodosum in 20 (including 10 streptococcal infections) and non-infectious inflammatory diseases in 8 patients. None of the 36 patients had tuberculosis or had been exposed to sulphonamides, phenytoin or hormonal contraceptives. There were eight patients in whom either the associated disease was not diagnosed, or there was no other disease. Conclusion Most cases of erythema nodosum are nowadays caused by non-mycobacterial infectious diseases or by non-infectious inflammatory disease

Wie wird das hamolytisch-uramische Syndrom des Kindesalters in der Schweiz erworben? [How is hemolytic-uremic syndrome in childhood acquired in Switzerland?]

Intestinal infections with shigatoxin-producing Escherichia coli or Shigella dysenteriae type I play a major role in the pathogenesis of the hemolytic-uremic syndrome in childhood. Escherichia coli has been repeatedly detected in the intestines of healthy cattle. Twenty-seven children with hemolytic-uremic syndrome were treated at our hospital between June 1990 and March 1997. Factors indicating a possible previous contact with bovine intestinal content were found in 18 out of the 27 patients: parents stockbreeders (n = 7), recent visit to a cowshed or contact with cowdung or manure (n = 5), residence in a rural cattle-breeding area (n = 5), or consumption of raw milk (n = 1). The factors mentioned were found in 5 out of 27 control patients (p < 0.01). Two children experienced hemolytic-uremic syndrome after a stay respectively in Egypt and Tunisia. Our results indicate an important source for acquisition of hemolytic-uremic syndrome in childhood. Observing simple hygienic rules such as washing of hands and pasteurization of milk is likely to have a positive influence on the incidence of this illness. There are also grounds to consider adding the hemolytic-uremic syndrome to the list of travel-related diseases

Amlodipine once-daily in systemic hypertension

The calcium channel blocker nifedipine is widely used in children with systemic hypertension: however, because of the short duration of action, three to four daily doses of the standard preparation are required. Amlodipine once-daily, a calcium channel blocker structurally related to nifedipine with an excellent bioavailability and a long elimination half-time, has been shown to reduce blood pressure in adults. No information is available on the use of amlodipine in childhood. The effects of amlodipine once-daily (5 to 10 mg) were therefore assessed in 28 paediatric patients with hypertension. Amlodipine was withdrawn in five patients who experienced oedema and flushing. In the remaining 23 patients blood pressure was significantly reduced 3 weeks after amlodipine (on average by 7/5 mm Hg) and further decreased at 12 weeks (by 21/12 mm Hg). Heart rate and body weight were unchanged. In eight patients concomitantly treated with cyclosporine, the blood level of this agent was stable throughout the study, thus not requiring any dose adjustment. CONCLUSION: The study illustrates the antihypertensive properties of amlodipine once-daily in paediatric hypertension. Amlodipine appears particularly indicated in patients concomitantly treated with cyclosporine